45 terminated. 45 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 45 | Terminated 45 |
| Phase 2 | 15 | Terminated 15 |
Follow Advanced Cancer: new trials by email Literature Review of Advanced Cancer trials Research Report on Advanced Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors BGB-B3227, Tislelizumab, Chemotherapy - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Terminated | BeiGene | 35 | 2024-09-11 | 2026-03-16 |
| A Study of PHN-010 in Patients With Advanced Solid Tumors PHN-010 - Lung Cancer, Colon Cancer | Phase 1 | Terminated | Pheon Therapeutics | 26 | 2024-07-01 | 2026-01-29 |
| A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers [14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir - Advanced Cancer | Phase 1 | Terminated | Viracta Therapeutics, Inc. | 8 | 2024-02-28 | 2025-01-20 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC | Phase 1 | Terminated | Mirati Therapeutics Inc. | 6 | 2023-08-07 | 2025-04-25 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) TT-816, A PD-1 inhibitor - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Teon Therapeutics, Inc. | 9 | 2022-08-29 | 2024-11-21 |
| A Study of DS-9606a in Patients With Advanced Solid Tumors DS-9606a - Advanced Cancer, Metastatic Cancer | Phase 1 | Terminated | Daiichi Sankyo | 88 | 2022-05-31 | 2026-03-20 |
| A Study Explore JS001+JS002 in Patients With Advanced Cancer JS001(Toripalimab)+JS002 - Advanced Cancer | Phase 1 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 9 | 2022-02-10 | 2024-03-26 |
| Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors TQB2858 injection - Advanced Cancer, Advanced Soft-tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 8 | 2022-01-14 | 2024-01-18 |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) MRTX849, BI 1701963 - Advanced Cancer, Metastatic Cancer | Phase 1 | Terminated | Mirati Therapeutics Inc. | 7 | 2021-07-28 | 2024-12-16 |
| Study of GNX102 in Patients With Advanced Solid Tumors GNX102 - Solid Tumor, Metastatic Cancer | Phase 1 | Terminated | GlycoNex, Inc. | 46 | 2020-07-29 | 2024-05-06 |
| NBE-002 in Patients With Advanced Solid Tumors NBE-002 - Advanced Solid Tumor, Advanced Cancer | Phase 1 / Phase 2 | Terminated | NBE-Therapeutics AG | 12 | 2020-06-19 | 2023-09-07 |
| Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers Ipilimumab, Nivolumab, Tilsotolimod - Advanced Cancer | Phase 1 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 25 | 2020-04-10 | 2024-10-18 |
| A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer LY3434172 - Advanced Cancer | Phase 1 | Terminated | Eli Lilly and Company | 10 | 2019-05-24 | 2025-01-15 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies Alomfilimab, Atezolizumab - Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Kymab Limited | 222 | 2019-01-28 | 2025-04-02 |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML FN-1501 - Advanced Cancer, Solid Tumors | Phase 1 | Terminated | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 67 | 2018-07-23 | 2023-10-13 |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. 177Lu-3BP-227 (also called 177Lu-IPN01087) - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 | Terminated | Ipsen | 14 | 2018-05-03 | 2023-12-12 |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies FS118, Paclitaxel - Advanced Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Terminated | invoX Pharma Limited | 80 | 2018-04-16 | 2025-07-01 |
| An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed BMS-986299, Nivolumab, Ipilimumab - Advanced Cancer | Phase 1 | Terminated | Bristol-Myers Squibb | 82 | 2018-04-05 | 2022-05-23 |
Showing 20 of 45. Sign in to see all of them.
Neoplasm Metastasis (13) · Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (7) · Stomach Neoplasms (6) · Pancreatic Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Esophageal Neoplasms (4) · Melanoma (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma (2)
Neoplasms (16) · Neoplasms by Histologic Type (15) · Neoplasms by Site (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Neoplastic Processes (13) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9) · Lung Diseases (9) · Neoplasms, Glandular and Epithelial (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9)
Nivolumab (6) · Irinotecan (4) · Docetaxel (3) · Ipilimumab (3) · pembrolizumab (3) · 130-nm albumin-bound paclitaxel (2) · 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline (2) · Albumin-Bound Paclitaxel (2) · Gemcitabine (2) · N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide (2) · Paclitaxel (2) · adagrasib (2) · AEG 35156 (1) · Ado-Trastuzumab Emtansine (1) · Capecitabine (1)
Bristol-Myers Squibb (4) · Eli Lilly and Company (4) · Mirati Therapeutics Inc. (3) · Pfizer (3) · Western Regional Medical Center (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · SGX Pharmaceuticals, Inc. (2) · Aegera Therapeutics (1) · Agenus Inc. (1) · Aminex Therapeutics, Inc. (1) · BeiGene (1) · Chinese Academy of Medical Sciences (1) · Daiichi Sankyo (1) · Endocyte (1) · EpicentRx, Inc. (1)
United States (34) · Australia (7) · France (7) · United Kingdom (7) · Canada (5) · Italy (5) · Belgium (4) · China (4) · Netherlands (3) · Poland (3) · Spain (3) · Taiwan (3) · Japan (2) · Switzerland (2) · Argentina (1)
Ai-Min Hui, MD, PhD (1) · Alan Tan, MD (1) · Ashish Sangal, MD (1) · Bryan Oronsky, MD (1) · Cynthia Lynch, MD (1) · Darrel P Cohen, MD, PhD (1) · Gary Schwartz, MD (1) · Howard Burris, MD (1)
PMID 24440085, PMID 29119276, PMID 33277223, PMID 34615718, PMID 36342102, PMID 39824531, PMID 42259602
2018 (3), 2017 (2), 2014 (1), 2015 (1), 2016 (1), 2019 (1)